The billion-dollar problem keeping GLP-1 drugs from patients

Pharmacist wearing mask explains medication to customer — Photo: worawit_j / Shutterstock

A drug that could help millions of Americans lose weight is sitting just out of reach, and the reason has nothing to do with whether it works.

Quick Take

Wegovy and Zepbound carry list prices topping $1,000 a month, pushing employer costs to $8,000 to $10,000 per patient each year even after rebates.
Only about a third of employer health plans cover GLP-1 drugs for weight loss, far below coverage for diabetes use.
Large companies report the drugs already eat up nearly 7 percent of total annual health claims at some firms.
New oral versions of these drugs cost employers roughly the same as the injections, dashing hopes for cheaper access.

The Sticker Shock Behind The Miracle Drug

Novo Nordisk prices Wegovy at $1,349 a month. Eli Lilly’s Zepbound runs $1,086. Insurers rarely pay full price, but even after discounts and rebates, employers still shell out $8,000 to $10,000 per patient every year. One employer guide puts the average annual list price for GLP-1 drugs at $12,000 before any negotiated breaks. That math turns a popular benefit into a budget headache fast.

Business leaders are not hiding their frustration. One chief executive told reporters he wants to cover these drugs for his workers but calls the price tag simply too expensive to sustain. That tension between wanting to help employees and protecting the bottom line sits at the center of nearly every benefits meeting happening right now.

Coverage Is Growing, But Slowly And Unevenly

Employer coverage for GLP-1 weight-loss drugs has climbed, but it still lags far behind coverage for diabetes treatment. Nearly every employer-sponsored plan covers these drugs when prescribed for diabetes, yet weight-loss coverage remains inconsistent. A 2024 survey found roughly one-third of employer health plans covered the drugs for both uses, marking a real increase from prior years.

Bigger companies move faster than smaller ones. Firms with deeper pockets and more negotiating leverage over drug pricing are far more likely to add coverage than small businesses running tighter margins. That gap creates a two-tier system where workers at large corporations often get access while employees at smaller firms get left out, regardless of medical need.

Why Some Employers Call Broad Coverage Unsustainable

A market trend report on employer approaches to these drugs put it bluntly: even though the therapies may pay off over a patient’s lifetime, current net prices make covering everyone who qualifies financially untenable for many companies. That is not an argument against the medicine. It is an argument about who foots the bill under today’s pricing structure.

The numbers back up the worry. At some large employers, GLP-1 prescriptions for weight loss already account for close to 7 percent of all annual health claims. Benefit consultants at the Kaiser Family Foundation found that many large employers are now considering scaling back coverage rather than expanding it, precisely because the cost curve keeps climbing.

Pills Were Supposed To Be The Fix. They Are Not.

Drugmakers rolled out oral versions of these medications hoping cheaper manufacturing would translate into cheaper bills. It has not worked out that way. Reporting on the new pill formulations found they cost employers roughly the same as the injectable versions, with list prices still landing between $1,000 and $1,350 a month before any insurance discount. That reality punctures a hope many benefit managers were counting on.

Employers now lean on tools like prior authorization, step therapy, and strict reauthorization rules to keep costs from spiraling further. Those controls frustrate patients who feel like they are jumping through hoops for medicine their doctor already approved. But without some kind of gatekeeping, benefit managers argue the math simply does not work at current prices.

What Would Actually Break The Logjam

The real fix here is not a mystery. Drug prices need to come down, or insurers need hard evidence that covering these drugs now saves money later through fewer hospital visits and less diabetes-related illness. Until manufacturers cut prices or long-term studies prove the savings, employers stuck between employee demand and shareholder pressure will keep rationing access to a drug that already works.